Health Care/Hospital
FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy
NANJING, China, Dec. 24, 2023 /PRNewswire/ -- The innovative development of biopharmaceuticals has ushered in a new era for disease treatment, bringing unprecedented hope to countless patients. However, the transition from basic research to clinical commercialization presents formidable challenge...
2023-12-25 10:15
2142
APL-2301, a compound developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia
SHANGHAI, Dec. 24, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its product, APL-23...
2023-12-24 17:53
2745
GenSci Launches Global Innovation Hub in Shanghai
The Establishment of the Facility Demonstrates the Company's Commitment to Delivering Differentiated Solutions to Gynecology and Pediatrics Challenges SHANGHAI, Dec. 22, 2023 /PRNewswire/ -- Changchun GeneScience Pharmaceutical ("GenSci"), a subsidiary of Changchun High-Tech Industries (Group), h...
2023-12-23 15:41
3063
Yoshitsu Co., Ltd Reports First Six Months of Fiscal Year 2024 Financial Results
TOKYO, Dec. 22, 2023 /PRNewswire/ -- Yoshitsu Co., Ltd ("Yoshitsu" or the "Company") (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, as well as other products inHong Kong, mainland China, Japan, North America...
2023-12-22 19:00
6460
Oncoshot Teams Up with Zhejiang Ablaze Medicine to Drive Data-Powered Drug Development in China
SINGAPORE, Dec. 22, 2023 /PRNewswire/ -- Oncoshot, an innovative health insights exchange platform leveraging AI and federated learning, today announced it has forged a strategic partnership with Zhejiang Ablaze Medicine, a leading service provider of end-to-end clinical trial solutions, to joint...
2023-12-22 13:26
2605
A Pioneer in Data Analytics Excellence: SIFT Analytics Group Drives Digital Transformations for Over 1,000 Businesses Across Southeast Asia
SINGAPORE, Dec. 19, 2023 /PRNewswire/ -- SIFT Analytics
2023-12-22 11:27
2973
Davos Communications Awards - BGI Genomics Inclusive Instagram Strategy Wins Gold Recognition
HONG KONG, Dec. 22, 2023 /PRNewswire/ -- BGI Genomics, the world's leading provider of integrated solutions for precision medicine, is pleased to announce winning Instagram Campaign (Gold) recognition at the Davos Communications Awards held onDecember 12, 2023. Organized by the World Communicati...
2023-12-22 08:19
2990
Jung Kwan Jang to Boost the Popularity of Red Ginseng by Employing various forms, from Film to Jelly
SEOUL, South Korea, Dec. 22, 2023 /PRNewswire/ -- Holding the top spot in global ginseng retail for a decade, Jung Kwan Jang declared to boost the popularity of red ginseng by employing various forms, from film to jelly. Red ginseng, which is a steamed and dried ginseng, has been traditionally c...
2023-12-22 07:00
2856
Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore
First drug to show both clinical symptomatic efficacy for five typical
Omicron-related symptoms and antiviral efficacy
SINGAPORE, Dec. 22, 2023 /PRNewswire/ -- Singapore-headquartered Juniper
Therapeutix
2023-12-22 07:00
2705
TransThera Announces the Global Multicenter Phase 3 Clinical Trial Completed First Patient Dosing in the US Evaluating Tinengotinib in FGFRi Relapsed/Refractory Patients with Cholangiocarcinoma
NANJING, China and GAITHURSBURG, Md., Dec. 21, 2023 /PRNewswire/ -- TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announces the first patient has been dosed in the US for the Phase 3 trial FIRST-308 of tinengotinib (TT-00420), ...
2023-12-21 21:45
1450
International Clinical Trial Results Released! Responding to the Virus Resurgence, Lianhua Qingwen Capsules Provide New Evidence
SINGAPORE, Dec. 21, 2023 /PRNewswire/ -- Recently, according to multiple reports from local Singaporean media, confirmed cases of COVID-19 are steadily increasing, with the average number of daily hospitalizations on the rise. The virus, once vigorously fought against, seems to be making a comeba...
2023-12-21 18:06
2539
CStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore
* The deal enables CStone to prioritize its resources to focus on the development of first-in-class and best-in-class therapies with global rights. * The deal enables Servier to potentially bring additional indications and accessibility of TIBSOVO® to patients in Greater China (including main...
2023-12-21 17:10
2456
Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline
SHANGHAI, Dec. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced that the U.S. Food and Drug Administration (FDA) had approved Nefecon® delayed rele...
2023-12-21 10:30
7157
EVERISE ANNOUNCES SUCCESSFUL CLOSURE OF INVESTMENT BY WARBURG PINCUS, JOINING BROOKFIELD FOR THE NEXT PHASE OF GROWTH
NEW YORK, SINGAPORE and MUMBAI, Dec. 21, 2023 /PRNewswire/ -- Everise, a leading global healthcare services outsourcing company, announced today the successful completion of the company's previously announced investment from Warburg Pincus. Warburg Pincus joins existing investorBrookfield, valuin...
2023-12-21 10:16
4787
ENA Building Momentum Globally in Support of Emergency Nurses
Partnerships help gold standard TNCC and ENPC courses reach more international ED nurses SCHAUMBURG, Ill., Dec. 21, 2023 /PRNewswire/ -- After a year dedicated to expanding its international connections, theEmergency Nurses Association stands poised to reach more emergency nurses globally with k...
2023-12-21 09:00
1908
BioCity announces the first patient dosed with its anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib/II Trial
WUXI, China, Dec. 20, 2023 /PRNewswire/ -- BioCity Biopharma today announced dosing of the first patient in a Phase Ib/II clinical trial of its anti-TIM-3 monoclonal antibody (mAb) BC3402 in combination with IMFINZI (durvalumab) for the treatment of advanced hepatocellular carcinoma (HCC) inCh...
2023-12-21 08:26
1660
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting
GAITHERSBURG, Md., Dec. 20, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2023-12-21 05:30
1755
/DISREGARD RELEASE: YS Biopharma/
We are advised by YS Biopharma Co., Ltd. (NASDAQ:YS) that journalists and other readers should disregard the news release, "YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting onDecember 28, 2023", issued on December 20, 2023 by YS Biopharma over PR Newswire, as the release contained err...
2023-12-21 05:15
2579
CellOrigin announced treatment of the first patient with CAR-M in China and reported the second generation of CAR-M for solid tumors
HANGZHOU, China, Dec. 20, 2023 /PRNewswire/ -- Recently, a CAR-macrophage therapy product (CAR-M) SY001 from CellOrigin Biotechnology (Hangzhou) Co., Ltd. was dosed to the first patient in a hospital inChina. "A single center, single-arm, dose-escalation, exploratory clinical trial to examine t...
2023-12-21 01:00
1697
EpiVax Licenses ISPRI Toolkit to Eisai for Preclinical in silico Immunogenicity Screening
PROVIDENCE, R.I., Dec. 21, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax"), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. ("Eisai") has licensed EpiVax's ISPRI toolkit for preclinical immunogenicity risk assessment of Eisai's robust biologic...
2023-12-20 23:45
1803
Week's Top Stories
Most Reposted
2024 Malaysia E-Commerce Product Selection Expo Attracts International Delegations
[Picked up by 314 media titles]
2024-12-02 12:06
AC Health makes critical HIV care more accessible to Filipinos with USAID support
[Picked up by 309 media titles]
2024-12-03 16:11
ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 299 media titles]
2024-11-28 17:24Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 289 media titles]
2024-11-29 20:33
Hong Kong Airlines Resumes Vancouver Service Offering Twice-weekly direct flights from 18 January 2025
[Picked up by 289 media titles]
2024-12-02 20:01
Most Read
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
2024-11-29 20:33
11349
China's spicy hotpot sets its sights on global market
2024-11-29 21:36
5070
CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China
2024-11-30 09:00
5054